Trilaciclib is under clinical development by G1 Therapeutics and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Trilaciclib’s likelihood of approval (LoA) and phase transition for Metastatic Colorectal Cancer took place on 28 Sep 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Trilaciclib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Trilaciclib (Cosela) is a potential antineoplastic agent with chemoprotective properties. It is formulated as lyophilized cake for solution for intravenous route of administration. Cosela is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).
Trilaciclib is under development for the treatment of small-cell lung cancer, metastatic bladder cancer (locally advanced or metastatic urothelial carcinoma), metastatic triple negative breast cancer, colon cancer, metastatic colorectal cancer, castrate-resistant prostate cancer, NSCLC as first line and chemotherapy-induced myelosuppression. It is administered through intravenous route. The drug candidate acts by targeting cyclin-dependent kinases (CDK) 4 and 6. It was also under development for the treatment of non-small cell lung cancer.
G1 Therapeutics overview
G1 Therapeutics is a biopharmaceutical company. It discovers, develops and commercializes therapeutics for the treatment of cancer. The company offers pipeline products that include COSELA (trilaciclib), a CDK4/6 inhibitor to preserve hematopoietic stem cell and immune system function during chemotherapy; G1T38, an oral CDK4/6 inhibitor served as backbone therapy for multiple combination regimens; Lerociclib; and G1T48, an oral selective estrogen receptor degrader. G1 Therapeutics discovers new small molecule-based methods that prevent the hematological side effects of cancer chemotherapy and exposure to ionizing radiation. The company also develops small molecules to target specific proteins associated with cell proliferation and growth. It operates through its laboratory located in Research Triangle Park. G1 Therapeutics is headquartered in Research Triangle Park, North Carolina, the US.
Quick View Trilaciclib LOA Data
|Highest Development Stage|